Challenges and future perspectives for minimal residual disease (MRD) in multiple myeloma
Bruno Paiva et al.
Can venetoclax be used to treat multiple myeloma (MM)?
The utility of measurable residual disease (MRD) assessment in acute myeloid leukemia (AML)
Gert J. Ossenkoppele
Evolving CLL treatments: creating choices and igniting discussions
Deborah Henderson et al.
Venetoclax in combination with antibodies in the treatment of CLL